Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I believe with all my heart and soul that the bad days are behind us and SVFC has started a long and steady climb up!
And where she stops no one knows!
GO SVFC
Yep, I know!! I was lucky and and got some .0011's
SVFC watch it closely now!!
beautiful hammer candlestick today!!!!!
http://stockcharts.com/h-sc/ui?s=SVFC
GO SVFC
I just received an e-mail from Frank Lorenzo with todays press release and an invitation to call him with any questions!!!!
Very professional and open with the shareholders IMO
I am feeling more and more confident about SVFC every day!!!!
nice close today!
GO SVFC
.0013's gone !!! .0014's up!!!
GO SVFC
.0013's getting ready to fall
GO SVFC
things may start to move very quickly, very shortly!!
HANG ON!!!
GO SVFC
nice bid support coming in!!
GO SVFC
well, well, well. what do ya know.....
SVFC is executing on its business plan and will soon be firing on all cylinders!!
SVFC is the chance of a lifetime! Don't miss it
Watch as the people rush in to take part in this SVFC rally. Looks like it's going to be a good day!!
$$$ Ka Ching $$$
Go SVFC
In reference to the ironridge press release,
The issue with Ironridge was made public by Intellicell in its SEC filings and public relations announcements, IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "the Ironridge case was settled in July, 2014 and there was no Final Enforcement but it was an Order that was complied with in July 2014. I believe this is just another ploy by Ironridge to hurt IntelliCell. We are exploring our legal options."
http://www.streetinsider.com/Press+Releases/IntelliCell+BioSciences+Complies+With+Court+Order+for+Ironridge+Settlement/9763163.html
SVFC + 30%
Feels like a breakout is near
Full STO @ 6.67 still extremely oversold!!
.002 is very doable tomorrow!
we may be able to turn this pop into a full reversal and close in on .003 by weeks end!
And with any good news.... Watch out!!
Either way SVFC deserves to much higher than where it is, and I believe the days ahead are going to be extremely bright for the true longs!
Go SVFC
I sent an e-mail first thing this morning and received a reply at 12:11pm
Go SVFC
I just revived an e-mail from SVFC
Hello Mr. Xxxxxxx
I just left you a Voicemail on xxx-xxx/xxxx
My name is Frank Lorenzo and your email has been forwarded to me from the staff at Intellicell.
I have well over 25 years of experience of corporate finance and investment banking experience and I have been working closely with Dr. Victor and his staff at Intellicell.
Although we are frustrated with the current price of Intellicell shares, we feel that as the Company begins to execute on our current business model, the Company’s valuation will become consistent with comparative public stem cell companies.
Intellicell is a Company that takes pride in its shareholder responsibility is committed towards corporate growth and expansion.
As you can see by the attachment, the investor link on our website as well as the recent press releases, Intellicell has made significant strides and we look forward to the future with continued optimism.
We appreciate your email and your continued support.
If you would like to discuss Intellicell further, please call me at 551 427 8476
Regards-
Frank
Frank Lorenzo – Advisor
Intellicell Biosciences, Inc.
460 Park Avenue – 17th floor
New York, NY 10022
www.intellicellbiosciences.com
Cell: 551 427 8476
Office: 212 249 3050
Fax 201 829 0845
lorenzofrank7@gmail.com
CONFIDENTIALITY NOTICE: This message (including any attachments) is intended solely for the use of INTELLICELL BIOSCIENCES, INC.. its affiliates and the individual addressee(s). This message may contain confidential and/or private information privileged to recipient or recipients named above. If you are not the authorized recipient(s), or the employee or agent responsible for delivering this message to the intended recipient(s), please immediately notify the sender by e-mail at the address shown above and delete this message from your system, other storage mechanism and/or shred the document and any attachments. Any unauthorized use, review or dissemination of this message in whole or in part by persons or entities other than the intended recipient is strictly prohibited. INTELLICELL BIOSCIENCES, INC. shall not be liable for the improper or incomplete transmission of the information contained in this communication nor for any delay in its receipt or damage to your system.
This may start moving very fast after lunch!
.002. Today?
Up up up and away! SVFC is having a good day
IntelliCell BioSciences Files Pre-IND With FDA for Osteoarthritis Lead by Dr. James Andrews
Quote:
Aug 1, 2014 IntelliCell BioSciences, Inc. (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stomovascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has filed its pre-IND with the FDA for a clinical trial in osteoarthritis of the knee under an Investigational New Drug Application (IND). Dr. James Andrews, the legendary orthopedic surgeon will be the principal investigator for the study. inVentiv Health Clinical will serve as the Clinical Research Organization (CRO) for the conduction of this clinical trial in osteoarthritis of the knee in accordance of an Investigational New Drug.
The clinical trial will be conducted at the Pensacola Center of the Andrews' Research and Educational Institute in conjunction with Dr. Adam Anz and Dr. Josh Hackel, prominent physicians at the Institute. To date, IntelliCell's technology for isolating stromal vascular fraction cells from the vasculature of adipose tissue has been used to successfully treat over 60 knees with results lasting as long as 5 years.
http://finance.yahoo.com/news/intellicell-biosciences-files-pre-ind-175253679.html
http://finance.yahoo.com/news/intellicell-biosciences-joins-forces-dr-183000618.html
http://www.fda.gov/Drugs/DevelopmentApprovalprocess/SmallBusinessAssistance/ucm069906.htm
http://finance.yahoo.com/news/inventiv-health-clinical-engaged-intellicell-143800120.html
Great post!!!
Thank you!
Go SVFC
Stem cells in the news
NY to invest $14M to promote stem cell education
Aug 6, 2014 3:08 a.m.
ALBANY, N.Y. - New York state is setting aside $14 million to promote stem cell research and education.
Gov. Andrew Cuomo announced the program on Wednesday. It will fund short-term stem cell research opportunities for middle- and high-school biology teachers.
Cuomo says giving teachers the opportunity to conduct stem-cell research is a good way of spurring student interest in the cutting-edge research. He says the initiative is intended to encourage more students to consider careers in the biomedical research field.
The money will also support direct research as well as efforts to encourage science museums to host lectures and exhibits detailing the importance and the challenges of stem cell research.
Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
http://m.njherald.com/w/main/story/118683660/
Go SVFC
I Can't resist buying more SVFC!
I will be on the ask first thing in the morning
Go SVFC
A "Great job" shout out to all those who were able to load last week!!!
Congratulations!!!!
SVFC will move up from these extremely oversold levels very soon!!
As always IMO
Go SVFC
SVFC is going to fly past .005 and take aim at .01
Strap in and hang on! Things are about to get very interesting around here!!
Go SVFC
SVFC
Are you ready for the BOUNCE?!!!!!
SVFC + BOUNCE = $$$$$$
SVFC + BOUNCE = $$$$$$
So I take it you are short SVFC?
Good luck with that!! Lol
SVFC is way way way oversold and will bounce!
Overbought Oversold
As a bound oscillator, the Stochastic Oscillator makes it easy to identify overbought and oversold levels. The oscillator ranges from zero to one hundred. No matter how fast a security advances or declines, the Stochastic Oscillator will always fluctuate within this range. Traditional settings use 80 as the overbought threshold and 20 as the oversold threshold. These levels can be adjusted to suit analytical needs and security characteristics. Readings above 80 for the 20-day Stochastic Oscillator would indicate that the underlying security was trading near the top of its 20-day high-low range. Readings below 20 occur when a security is trading at the low end of its high-low range.
http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:stochastic_oscillator_fast_slow_and_full
Go SVFC
Full STO is at 2.38 and anything below 20 is considered over sold
http://stockcharts.com/h-sc/ui?s=SVFC
The bounce is coming and it will be HUGE!!!
Go SVFC
SVFC is soooooo oversold!!!!
Huge bounce coming!!!!
It's happening!! Stem cells are becoming the the norm! Soon stem cell treatments will replace outdated medicines and traumatic surgeries to treat and (cure) everything from arthritis to cancer!!! And SVFC has the worlds best and most efficient method to do this!! And they have a U. S. Patent (granted) and international patents pending!!!
Stem cells in the news
Cedars-Sinai Heart Institute Opens First-of-its-Kind Research Stem Cell Clinic for Cardiac Patients
Physicians to Devise Comprehensive Treatment Strategies, Evaluate Patients for Inclusion in Ongoing Stem Cell Clinical Trials
Released: 12-Aug-2014 8:00 AM EDT
Source Newsroom: Cedars-Sinai Medical Center
more news from this source
Contact Information
Available for logged-in reporters only
Newswise — LOS ANGELES (Aug. 12, 2014) – Regenerative medicine experts at the Cedars-Sinai Heart Institute have opened a new clinic to evaluate heart and vascular disease patients for participation in stem cell medical studies.
Led by Eduardo Marbán, MD, PhD, director of the Cedars-Sinai Heart Institute, and Timothy Henry, MD, director of the Heart Institute’s Cardiology Division, the doctors and researchers at the Cedars-Sinai Heart Institute Regenerative Medicine Clinic use a scientific approach to assess the possible benefits of stem cells to repair damaged or diseased cardiovascular tissues. The clinic is believed to be the first at a major U.S. academic medical center dedicated to matching patients with appropriate stem cell clinical trials, whether those research interventions are available at the medical center or at other institutions.
The Heart Institute Regenerative Medicine Clinic offers consultative services for patients with heart and vascular disease who may qualify for investigative stem cell therapy. The goal is to provide research options to patients who remain symptomatic on their current management regimen, or for patients with stable heart disease who are concerned about disease progression.
“Over the past decade, medical experts have predicted that in the future, stem cell therapies would transform heart disease treatment and save lives,” said Shlomo Melmed, MD, dean of the Cedars-Sinai faculty and the Helene A. and Philip E. Hixon Distinguished Chair in Investigative Medicine. “At Cedars-Sinai, we have a track record of successfully directing cardiac stem cell studies as well as transferring innovations from the laboratory to the patient bedside.”
In 2009, Marbán and his team completed the world’s first procedure in which a patient’s own heart tissue was used to grow specialized heart stem cells. The specialized cells were then injected back into the patient’s heart in an effort to repair and re-grow healthy muscle in a heart that had been injured by a heart attack. Results, published in The Lancet in 2012, showed that one year after receiving the stem cell treatment, heart attack patients demonstrated a significant reduction in the size of the scar left on the heart muscle after a heart attack.
Henry has served as principal investigator of multiple large, multicenter trials in acute coronary syndromes, myocardial infarction and angiogenesis, including several ongoing cardiovascular stem cell trials. He also is principal investigator for one of seven NIH Clinical Cardiovascular Stem Cell Centers.
“Our goal is to help make stem cells a regular treatment option for heart disease,” Henry said. “Right now, many patients with advanced heart disease have limited treatment options. Stem cells offer not only hope but a real chance of a game-changing treatment.”
As part of each patient’s assessment in the Heart Regenerative Medicine Clinic, physicians will evaluate patients interested in participating in stem cell clinical trials at Cedars-Sinai and, for patients willing to travel at other medical institutions across the nation. For patients willing to travel to participate in research, Cedars-Sinai physicians will work closely with investigators at other centers to expedite referrals and seamlessly transfer all relevant medical records.
“Patients who have battled heart failure, heart attacks and severe hypertension for years might not be aware of new options that could improve their health and quality of life,” Marbán said. “Not every patient will find a suitable stem cell clinical trial, but we are focused on finding each patient the most advanced treatment for their disease.”
To make an appointment for a preliminary evaluation, patients should call toll free 855-STEM-WORK (855-783-6967) or 310-423-1231.
About the Cedars-Sinai Heart Institute
The Cedars-Sinai Heart Institute is internationally recognized for outstanding heart care built on decades of innovation and leading-edge research. From cardiac imaging and advanced diagnostics to surgical repair of complex heart problems to the training of the heart specialists of tomorrow and research that is deepening medical knowledge and practice, the Cedars-Sinai Heart Institute is known around the world for excellence and innovations.
Go SVFC
Stem cells in the news
Nature MedicineGo
Menu
NATURE MEDICINE | NEWS
Print
Email
Share/bookmark
Letter campaign sought to pressure FDA action on stem cell clinics
Elie Dolgin
Nature Medicine 20, 796–797 (2014) doi:10.1038/nm0814-796
Published online 06 August 2014
Article tools
Download PDF
Reprints
Rights & permissions
Article metrics
Unregulated stem cell clinics are proliferating throughout the US. A case in point is the Cell Surgical Network (CSN), which has grown over the last two years to encompass 42 independent centers that offer to inject patients' own stem cells back into their bodies in an effort to treat any of more than 30 different diseases and injuries.
Affiliate members of the network, which now spans 22 US states, claim their therapies involve minimal manipulation of a person's own tissue—specifically, the adipose-derived stromal vascular fraction (SVF), a soup of mesenchymal stem cells and other cell populations found in fat—all isolated in a closed, sterile procedure. This surgical procedure, the CSN maintains, falls outside the regulatory authority of the US Food and Drug Administration (FDA). But Leigh Turner disagrees.
Turner, a bioethicist at the University of Minnesota in Minneapolis, wrote a letter last year to Celia Witten, director of the Office of Cellular, Tissue and Gene Therapy at the FDA's Center for Biologics Evaluation and Research, urging the agency to investigate whether the CSN (known then as the California Stem Cell Treatment Center) was violating federal regulations governing the administration of stem cell–based products. After hearing nothing back for 17 months and counting, Turner decided to ask for help from others: at the International Society for Stem Cell Research (ISSCR) Annual Meeting held in Vancouver, Canada, on 19 June, he called on the regenerative medicine community to join him in a letter-writing campaign to pressure the FDA to crack down on CSN affiliates and other clinics offering unapproved stem cell therapies.
“The United States looks a lot like the very countries that we tend to disparage as being destinations for so-called stem cell tourists,” Turner told Nature Medicine. “This is a large-scale domestic problem.”
Mark Berman, MD, Cell Surgical Network
Time Machine heals all wounds? The CSN Time Machine combines a centrifuge and incubator to prepare patients' own fat-derived stem cells.
According to figures compiled by Paul Knoepfler, a stem cell biologist and blogger at the University of California–Davis, there are now more than 100 clinics offering stem cell therapies in the US—“and it could even be as high as 200”—with CSN and the Stem MD chain providing the largest known allied networks. Knoepfler, who interviewed the founders of CSN last year (see go.nature.com/bbSfqZ), describes Turner's decision to go public with his letter as a “gutsy move,” as Turner “now makes himself the public face of opposition to the dubious, unregulated action of the companies about which he is particularly concerned,” Knoepfler says.
Although no one has yet publicly announced the intention to write a comparable letter, experts in the field generally support Turner's call to action. “There is a growing frustration within the community about these kind of clinics,” says Tim Caulfield, a health law and policy expert at the University of Alberta in Edmonton, Canada, who is on the committee tasked with updating the ISSCR's Guidelines for the Clinical Translation of Stem Cells. “I do think it is important for the science community to speak up.”
“If it comes from a larger group of professionals, and there's some type of repetition, I think it's going to get the message out that there are these people doing these fraudulent things,” adds Zubin Master, a bioethicist and stem cell policy researcher at Albany Medical College in New York. At a minimum, Master notes that public letter writing could help counter the voices in free-market think tanks and regenerative medicine companies that are advocating for deregulation for stem cell products generally (see Nature 510, 336–337, 2014).
Such action from the stem cell community is especially important, experts say, following the ISSCR's aborted 'Submit a Clinic' initiative, which, starting in 2010, invited the public to tender the names of specific stem cell providers for review. ISSCR officials planned to then ask those clinics for documentation demonstrating appropriate oversight and medical evidence for the treatments on offer, but within less than a year the society shelved the project in the face of numerous legal challenges.
A man of letters
Turner has a history of writing letters to the FDA. In February 2012, he appealed to agency officials to examine Celltex Therapeutics, a Texas-based company that was working with South Korea's RNL Bio to offer autologous stem cell treatments for a range of ailments. (Governor Rick Perry of Texas, who suffered from recurring back pain, was the company's first patient in July 2011.)
Although Turner concedes that he has no way of knowing whether his letter had any impact, within two months of his sending the petition the FDA had inspected Celltex's manufacturing facilities, finding that the company's therapy constituted a biologic drug in need of regulatory approval. Celltex now provides only cell-processing and cell-banking services in the US; when clients wish to use the cells for therapeutic purposes, Celltex releases the cells to independent physicians in Mexico, where regulations are less restrictive.
As for Turner, after he publicly disclosed that he had written to the FDA asking the agency to investigate Celltex, attorneys for the Texas firm wrote to Turner's employers at the University of Minnesota threatening litigation. “It's a bit anxiety provoking,” he says. “There's also the practical matter that these clashes can be exhausting and time-consuming.”
Despite these drawbacks, Turner reached out to FDA officials again in December 2012 to voice concerns over Precision StemCell, an Alabama clinic that was offering autologous stem cell therapies to treat amyotrophic lateral sclerosis, multiple sclerosis and joint pain. (He blogged about the letter six months later.) There is no public record of an FDA inspection or agency warning letter to Precision StemCell, but by mid-2013 the company had moved its operations to Bogotá, Colombia.
Besides those publicly disclosed, Turner says he has sent letters relating to another half-dozen business operations marketing similar stem cell interventions in the US. “Hopefully the FDA is paying attention,” he says, “and hopefully they do something.”
Awaiting an answer
At press time, Turner was still awaiting an answer from the FDA regarding his letter about the CSN. (Agency officials declined to comment for this story, citing FDA policy not to discuss complaints submitted by individuals or the status of companies in dispute.)
CSN founder Mark Berman, a cosmetic surgeon who specializes in fat transfer, believes that the FDA has rightly cracked down on certain stem cell products, such as the one sold by Colorado-based Regenerative Sciences, which a US appeals court ruled earlier this year falls under the agency's purview. He stresses, though, that CSN does not require FDA oversight because the SVF used in the network's therapy is obtained using off-label surgical methods, not laboratory procedures, in a way that poses no risk of disease transmission.
Berman told Nature Medicine that he has no intention to pursue litigation against Turner. He wrote to Turner personally after the ISSCR presentation in June to explain his position. And he is already in communication with the FDA about running a clinical trial to validate the network's cell preparation equipment, all of which is currently approved for other surgical applications but which the CSN would test specifically for the extraction of SVF in the trial.
Mark Berman, MD, Cell Surgical Network
Stromal salve: The stromal vascular fraction is filtered ahead of transplantation.
According to Berman, such a trial is not required other than for marketing purposes relating to the equipment (which he has dubbed the CSN Time Machine), but he hopes it will help add scientific weight to the therapy and thus quiet the network's vocal critics. He also notes that CSN has an ongoing safety study listed on ClinicalTrials.gov (registered under NCT01953523) that has documented few adverse effects of the SVF therapy to date.
“We're not a fly-by-night organization,” Berman says. “We're not exploiting anyone. We're involved with doctors who are highly regarded within their own specialties. We're not doing anything for which the FDA should or does have opposition.”
Go SVFC
Stem cells in the news
Nominated for the Ice Bucket Challenge? Donate to this Morally Acceptable Alternative!
August 16, 2014Leave a Comment
As the ALS association is supportive of embryonic stem cell research, we as catholics ought not to support it, especially when there are morally acceptable alternatives. The John Paul II Medical Research Institute is just that, a morally acceptable alternative to the ALS Association.
If you are nominated to do the Ice Bucket challenge, donate to the JPII Medical Research Institute:
SUBSCRIBE BY EMAIL TO FR. MICHAEL DUFFY
Capital Campaign
The John Paul II Medical Research Institute (JP2MRI) is excited to kick off 2014 with a One Million Dollar Capital Campaign Drive to start the process of developing adult stem cell therapies. The JP2MRI focuses on regenerative medicine in which adult stem cells will be used to treat patients with chronic diseases like cancer, pulmonary disease and neurodegenerative disorders. Seventy-five percent of healthcare costs are due to chronic diseases, with many of these conditions lacking any medical cures. Adult stem cells have the potential to repair damaged organs, which in return would decrease healthcare costs and restore an improved quality of life for patients. Before the Institute can initiate adult stem cell clinical trials, the FDA requires that adult stem cells need to be manufactured in a “clean room” or sterile room.
The cost to build and initiate the operation is anticipated to be 1 million dollars. Funds raised from the One Million Dollar Capital Campaign Drive will be used to help build the clean room, lease additional laboratory space, hire scientific personnel and purchase necessary laboratory equipment to develop adult stem cell therapies.
The John Paul II Medical Research Institute is a 501(c)(3) tax-exempt public charity, as defined by the Internal Revenue Service. Your gift to the John Paul II Medical Research Institute may qualify as a charitable deduction for federal tax purposes as permitted by law. The support of donors is at the heart of advancing research and education at John Paul II Medical Research Institute. Your generous donations enable our staff of physicians, scientists, and researchers to advance cutting edge basic and clinical research in adult and umbilical cord stem cell research that reflects pro-life values.
Our donors have an opportunity to help find better treatments for cardiopulmonary disease, neuromuscular disease, cancer and other conditions that could benefit from adult and umbilical cord stem cells.
Please help the Institute by making a donation.
To donate, please click on the Paypal Icon [HERE] or send a check to the address below.
Thank You.
Checks can be made payable to: John Paul II Medical Research Institute
John Paul II Medical Research Institute
540 E. Jefferson St.
Suite 305
Iowa City, IA 52245
- See more at: http://www.patheos.com/blogs/frmichaelduffy/2014/08/nominated-for-the-ice-bucket-challenge-donate-to-this-morally-acceptable-alternative/#sthash.GcpzV1MP.dpuf
Go SVFC
Not realy.
The low of the day was .0011
But nice try.
Oh, and by the way.....
SVFC to da moon!!!!
I know! That's what makes this so exciting!!! Unlimited upside and only 4% downside
Go SVFC
So you're saying only 4% downside and unlimited upside?
Whoo hoo!
Go SVFC!!!!!
Are you starting to connect the dots yet? SVFC is a gold mine!!!!!